tiprankstipranks
Enliven Therapeutics (ELVN)
NASDAQ:ELVN
US Market

Enliven Therapeutics (ELVN) Financial Statements

267 Followers

Enliven Therapeutics Financial Overview

Enliven Therapeutics's market cap is currently ―. The company's EPS TTM is $-1.926; its P/E ratio is -11.43; Enliven Therapeutics is scheduled to report earnings on August 8, 2024, and the estimated EPS forecast is $-0.55. See an overview of income statement, balance sheet, and cash flow financials.
Mar 24Sep 23Jun 23Apr 23Jan 23
Income Statement-
Total Revenue-----
Gross Profit-----
EBIT$ -25.99M$ -24.25M$ -16.72M$ -116.23K$ -58.88K
EBITDA$ -25.91M$ -24.17M$ -17.48M--
Net Income Common Stockholders$ -22.74M$ -20.77M$ -16.72M$ -116.23K$ -58.88K
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 320.50M$ 263.48M$ 277.87M$ 338.86K$ 323.89K
Total Assets$ 342.78M$ 274.04M$ 288.50M$ 1.79M$ 797.20K
Total Debt$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Net Debt$ -320.50M$ -263.48M$ -277.87M$ -338.86K$ -323.89K
Total Liabilities$ 25.07M$ 12.29M$ 9.51M$ 233.55K$ 157.81K
Stockholders Equity$ 317.71M$ 261.75M$ 278.99M$ 1.56M$ 639.39K
Cash Flow-
Free Cash Flow$ -23.38M$ -15.91M$ -12.14M$ -99.53K-
Operating Cash Flow$ -23.36M$ -15.89M$ -12.05M$ -74.29K-
Investing Cash Flow$ -17.89M$ -35.55M$ -151.52M$ -25.23K-
Financing Cash Flow$ 90.27M$ -425.00K$ -2.82M$ 114.50K-
Currency in USD

Enliven Therapeutics Earnings and Revenue History

Enliven Therapeutics Debt to Assets

Enliven Therapeutics Cash Flow

Enliven Therapeutics Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis